Facebook Linkedin RSS Twitter Youtube
Home 2024

Merck & Co

Absci Eyes Busy 2025 as Lead AI-Designed Candidate Heads for Clinic
Artificial Intelligence

Absci Eyes Busy 2025 as Lead AI-Designed Candidate Heads for Clinic

Top 10 Best Selling Drugs
A-Lists

Top 10 Best Selling Drugs

Merck to Acquire EyeBio for Up to $3B, Re-Entering Eye Drug Space
Drug Discovery

Merck to Acquire EyeBio for Up to $3B, Re-Entering Eye Drug Space

NIIMBL Backs Bioprocess Tech and Training Innovation in Funding Round
Bioprocessing

NIIMBL Backs Bioprocess Tech and Training Innovation in Funding Round

MilliporeSigma Launches All-in-One Genetic Stability Assay for Biosafety Testing
Bioprocessing

MilliporeSigma Launches All-in-One Genetic Stability Assay for Biosafety Testing

Seaport Therapeutics Launches with $100M Series A
Drug Discovery

Seaport Therapeutics Launches with $100M Series A

With $86M Oversubscribed Public Offering, Absci Eyes 2025 IND for Lead Candidate
Artificial Intelligence

With $86M Oversubscribed Public Offering, Absci Eyes 2025 IND for Lead Candidate

HCP Monitoring from Bench through Commercialization
Bioprocessing

HCP Monitoring from Bench through Commercialization

GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines
Bioprocessing

GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines

JPM: More M&A “Firepower” in Store for 2024, EY Predicts
Drug Discovery

JPM: More M&A “Firepower” in Store for 2024, EY Predicts

123...41Page 1 of 41
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.